97679811 - THERADIGM

Information

• Trademark
• 97679811

• Source

• Serial Number

  97679811

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  November 16, 2022
  3 years ago

• Transaction Date

  May 25, 2025
  8 months ago

• Status Date

  May 23, 2025
  8 months ago

• Published for Opposition Date

  October 10, 2023
  2 years ago

• Location Date

  December 05, 2023
  2 years ago

• Status Code

  732

• Current Location

  INTENT TO USE SECTION

  Employee Name

  MAI, TINA

• Attorney Docket Number

  399247-1

  Attorney Name

  Michael A. Geller

  Law Office Assigned Location Code

  M80

• Owners

  • VESTA THERAPEUTICS, INC

Case File Statements

• GS0401: Biomanufacturing for others, namely, manufacturing of biologics, cells, scaffolds and matrices, and related biological materials using biological organisms in the manufacturing process
• GS0051: Biologics, namely, cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely, stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism
• GS0011: Biologics, namely, cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely, cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely, cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances
• GS0441: Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism
• GS0421: Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells

Case File Event Statements

• 11/19/2022 - 3 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 12/7/2022 - 3 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 8/29/2023 - 2 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 8/31/2023 - 2 years ago

  4 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 9/20/2023 - 2 years ago

  5 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 10/10/2023 - 2 years ago

  6 - PUBLISHED FOR OPPOSITION Type: PUBO

• 10/10/2023 - 2 years ago

  7 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 10/26/2023 - 2 years ago

  8 - ASSIGNED TO EXAMINER Type: DOCK

• 12/5/2023 - 2 years ago

  9 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 5/22/2024 - a year ago

  10 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 5/22/2024 - a year ago

  12 - SOU EXTENSION 1 GRANTED Type: EX1G

• 5/22/2024 - a year ago

  11 - SOU EXTENSION 1 FILED Type: EXT1

• 11/26/2024 - a year ago

  16 - SOU EXTENSION 2 GRANTED Type: EX2G

• 5/23/2025 - 8 months ago

  18 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 5/23/2025 - 8 months ago

  20 - SOU EXTENSION 3 GRANTED Type: EX3G

• 5/24/2025 - 8 months ago

  21 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 5/23/2025 - 8 months ago

  19 - SOU EXTENSION 3 FILED Type: EXT3

• 5/23/2024 - a year ago

  13 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 11/25/2024 - a year ago

  14 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 11/25/2024 - a year ago

  15 - SOU EXTENSION 2 FILED Type: EXT2

• 3/3/2025 - 11 months ago

  17 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA